Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men.
Atherogenic dyslipidemia
Body weight
Cardiovascular risk
Mirtazapine
TG/HDL-C ratio
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
29
01
2023
accepted:
23
02
2023
medline:
9
8
2023
pubmed:
9
3
2023
entrez:
8
3
2023
Statut:
ppublish
Résumé
Treatment with mirtazapine, a widely prescribed antidepressant, has been linked to weight gain and dyslipidemia. Whether dyslipidemia occurs secondary to increased appetite due to antidepressant treatment, or due to direct pharmacological effects of mirtazapine is unknown. The aim of this analysis is to complement our previously published results of the effect of mirtazapine on metabolism and energy substrate partitioning from a proof-of-concept, open-label clinical study (ClinicalTrials.gov NCT00878540) in 12 healthy males (20-25 years). We report the effect of a seven-day administration of mirtazapine 30 mg per day on weight and lipid metabolism in healthy men under highly standardized conditions with respect to diet, physical activity and day-night-rhythm and under continuous clinical observation. After a 7-day administration of mirtazapine 30 mg, we observed a statistically significant increase in triglyceride levels (mean change + 4.4 mg/dl; 95% CI [- 11.4; 2.6]; p = 0.044) as well as TG/HDL-C ratio (mean change + 0.2; 95% CI [- 0.4; 0.1]; p = 0.019) and a decrease in HDL-cholesterol (mean change - 4.3 mg/dl; 95% CI [2.1; 6.5]; p = 0.004), LDL-cholesterol (mean change - 8.7 mg/dl; 95% CI [3.8; 13.5]; p = 0.008), total cholesterol (mean change - 12.3 mg/dl; 95% CI [5.4; 19.1]; p = 0.005), and non-HDL-C (mean change - 8.0 mg/dl; 95% CI [1.9; 14.0]; p = 0.023). Notably, weight (mean change - 0.6 kg; 95% CI [0.4; 0.8]; p = 0.002) and BMI (mean change - 0.2; 95% CI [0.1; 0.2]; p = 0.002) significantly decreased. No change in waist circumference (mean change - 0.4 cm; 95% CI [- 2.1; 2.9]; p = 0.838) or waist-to-hip-ratio (mean change 0.0; 95% CI [- 0.0; 0.0]; p = 0.814) was observed. This is the first study showing unfavorable changes in lipid metabolism under mirtazapine in healthy individuals despite highly standardized conditions including dietary restriction, and despite the observation of a decrease of weight. Our findings support the hypothesis that mirtazapine has direct pharmacological effects on lipid metabolism. ClinicalTrials.gov: NCT00878540.
Identifiants
pubmed: 36890393
doi: 10.1007/s00210-023-02448-y
pii: 10.1007/s00210-023-02448-y
pmc: PMC10409833
doi:
Substances chimiques
Antidepressive Agents
0
Cholesterol, HDL
0
Mirtazapine
A051Q2099Q
Triglycerides
0
Banques de données
ClinicalTrials.gov
['NCT00878540']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1999-2008Informations de copyright
© 2023. The Author(s).
Références
Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig W. Inflammation and Cardiovascular Disease: The Future. Eur Cardiol. 2021 May 17;16:e20. doi: 10.15420/ecr.2020.50. PMID: 34093741; PMCID: PMC8157394.
Borén J, Chapman MJ, Krauss RM et al (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41:2313–2330
doi: 10.1093/eurheartj/ehz962
pubmed: 32052833
pmcid: 7308544
Chan DC, Watts GF, Ng TW et al (2008) Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest 38:743–751
doi: 10.1111/j.1365-2362.2008.02019.x
pubmed: 18837799
Croom KF, Perry CM, Plosker GL (2009) Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 23:427–452
doi: 10.2165/00023210-200923050-00006
pubmed: 19453203
De Boer T, Nefkens F, Van Helvoirt A (1994) The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 253:R5-6
doi: 10.1016/0014-2999(94)90778-1
pubmed: 7912194
Fisfalen ME, Hsiung RC (2003) Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 160:797
doi: 10.1176/appi.ajp.160.4.797
pubmed: 12668379
Fulda S, Kloiber S, Dose T et al (2013) Mirtazapine provokes periodic leg movements during sleep in young healthy men. Sleep 36:661–669
doi: 10.5665/sleep.2622
pubmed: 23633748
pmcid: 3624820
Ganda OP, Bhatt DL, Mason RP et al (2018) Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol 72:330–343
doi: 10.1016/j.jacc.2018.04.061
pubmed: 29935936
Gartlehner G, Thieda P, Hansen RA et al (2008) Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. Drug Saf 31:851–865
doi: 10.2165/00002018-200831100-00004
pubmed: 18759509
Hennings JM, Ising M, Grautoff S et al (2010) Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Exp Clin Endocrinol Diab Off J German Soc Endocrinol German Diab Assoc 118:98–100
doi: 10.1055/s-0029-1237361
Hennings JM, Schaaf L, Fulda S (2012) Glucose metabolism and antidepressant medication. Curr Pharm Des 18:5900–5919
doi: 10.2174/138161212803523662
pubmed: 22681169
Hennings JM, Heel S, Lechner K, Uhr M, Dose T, Schaaf L, Holsboer F, Lucae S, Fulda S, Kloiber S (2019) Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men. JCI Insight. 4(1):e123786. https://doi.org/10.1172/jci.insight.123786
Hieronimus B, Stanhope KL (2020) Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII. Curr Opin Lipidol 31:20–26
doi: 10.1097/MOL.0000000000000653
pubmed: 31789670
pmcid: 7413299
Himmerich H, Fulda S, Schaaf L et al (2006) Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 29:170
doi: 10.2337/diacare.29.01.06.dc05-1762
pubmed: 16373922
Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15:252–260
doi: 10.2174/1871530315666150623092031
pubmed: 26100432
Kopf D, Westphal S, Luley CW et al (2004) Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 24:527–531
doi: 10.1097/01.jcp.0000138762.23482.63
pubmed: 15349009
Kraus T, Haack M, Schuld A et al (2002) Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35:220–225
doi: 10.1055/s-2002-36390
pubmed: 12518269
Lechner K, Halle M (2019) Are atherogenic lipoprotein phenotype and inflammation indicative of plaque phenotype and clinical stability in coronary artery disease? JAMA Cardiology 4:950–951
doi: 10.1001/jamacardio.2019.2261
pubmed: 31314043
Lechner K, McKenzie AL, Kränkel N et al (2020a) High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation. Metab Syndr Relat Disord 18:176–185
doi: 10.1089/met.2019.0115
pubmed: 32119801
pmcid: 7196362
Lechner K, Kessler T, Schunkert H (2020b) Should we use genetic scores in the determination of treatment strategies to control dyslipidemias? Curr Cardiol Rep 22:146
doi: 10.1007/s11886-020-01408-9
pubmed: 32926241
Lechner K, Lechner B, Crispin A et al (2021) Waist-to-height ratio and metabolic phenotype compared to the Matsuda index for the prediction of insulin resistance. Sci Rep 11:8224
doi: 10.1038/s41598-021-87266-z
pubmed: 33859227
pmcid: 8050044
McIntyre RS, Soczynska JK, Konarski JZ et al (2006) The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 5:523–537
doi: 10.1517/14740338.5.4.523
pubmed: 16774491
McIntyre RS, Park KY, Law CWY et al (2010) The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 24:741–753
doi: 10.2165/11533280-000000000-00000
pubmed: 20806987
Nicholas LM, Ford AL, Esposito SM et al (2003) The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 64:883–889
doi: 10.4088/JCP.v64n0805
pubmed: 12927002
Pan A, Keum N, Okereke OI et al (2012) Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35:1171–1180
doi: 10.2337/dc11-2055
pubmed: 22517938
pmcid: 3329841
Penninx B, Lange SMM (2018) Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci 20:63–73
doi: 10.31887/DCNS.2018.20.1/bpenninx
pubmed: 29946213
pmcid: 6016046
Puzantian T (1998) Mirtazapine, an antidepressant. Am J Health-Syst Pharm 55:44–49
doi: 10.1093/ajhp/55.1.44
pubmed: 9437474
Roose SP (2003) Compliance: the impact of adverse events and tolerability on the physician’s treatment decisions. Eur Neuropsychopharmacol 13(Suppl 3):S85-92
doi: 10.1016/S0924-977X(03)00097-X
pubmed: 14550581
Samuel VT, Shulman GI (2016) The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 126:12–22
doi: 10.1172/JCI77812
pubmed: 26727229
pmcid: 4701542
Titchenell PM, Quinn WJ, Lu M et al (2016) Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab 23:1154–1166
doi: 10.1016/j.cmet.2016.04.022
pubmed: 27238637
pmcid: 4909537
Vancampfort D, Stubbs B, Mitchell AJ et al (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry : Official Journal of the World Psychiatric Association (WPA) 14:339–347
doi: 10.1002/wps.20252
pubmed: 26407790
Vergallo R, Porto I, Crea F (2019a) Are atherogenic lipoprotein phenotype and inflammation indicative of plaque phenotype and clinical stability in coronary artery disease?—Reply. JAMA Cardiology 4:951–952
doi: 10.1001/jamacardio.2019.2231
pubmed: 31314049
Vergallo R, Porto I, D’Amario D et al (2019b) Coronary atherosclerotic phenotype and plaque healing in patients with recurrent acute coronary syndromes compared with patients with long-term clinical stability: an in vivo optical coherence tomography study. JAMA Cardiol 4:321–329
doi: 10.1001/jamacardio.2019.0275
pubmed: 30865212
pmcid: 6484796
Watanabe N, Omori IM, Nakagawa A et al (2010) Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 24:35–53
doi: 10.2165/11319480-000000000-00000
pubmed: 20030418
Wittchen HU, Lachner G, Wunderlich U et al (1998) Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 33:568–578
doi: 10.1007/s001270050095
pubmed: 9803825
Zimmermann U, Kraus T, Himmerich H et al (2003) Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37:193–220
doi: 10.1016/S0022-3956(03)00018-9
pubmed: 12650740